Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 9/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.37 |
| ▸ | NAMPT | P43490 | 2/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11896028 | 0.88 | AHCY (0.53) | AHCYALDH1A1NAMPTGFERGAA | |
| SCHEMBL11903764 | 0.85 | AHCY (0.65) | AHCY | |
| SCHEMBL11903755 | 0.84 | AHCY (0.53) | AHCYACKR3 | |
| SCHEMBL1197505 | 0.81 | AHCY (0.51) | AHCYNAMPT | |
| SCHEMBL11974060 | 0.81 | AHCY (0.49) | AHCYALDH1A1NAMPTGFERGAA | |
| SCHEMBL11895664 | 0.81 | AHCY (0.50) | AHCYNAMPT | |
| Hydrochloric Acid SCHEMBL11896407 | 0.80 | AHCY (0.51) | AHCYALDH1A1NAMPTGFERGAA | |
| SCHEMBL12720680 | 0.80 | AHCY (0.49) | AHCYALDH1A1NAMPTGFERGAA | |
| SCHEMBL11973976 | 0.79 | AHCY (0.61) | AHCYALDH1A1NAMPTGFERGAA | |
| Hydrochloric Acid SCHEMBL11895705 | 0.78 | AHCY (0.63) | AHCYALDH1A1NAMPTGFERGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513235-B2 | Homocysteine synthase inhibitor | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-08-20 | — | — | US | disclosed |
| EP-2486925-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-08-15 | — | — | EP | disclosed |
| US-20120196824-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196824-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | FABP7, TIMP3, MMP11 | AHCY 4108/4885ALDH1A1 180/4885ACKR3 1777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.